Vito Palombella, PhD Joins Surface Oncology As Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Surface Oncology, Inc. (Surface), a leader in the development of next-generation cancer immunotherapies, announced today the appointment of Vito J. Palombella, PhD, as Chief Scientific Officer. Dr. Palombella brings twenty years of scientific leadership and experience advancing first-in-class therapeutic programs, and a successful track record of building drug discovery and development organizations.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.